Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 1, 2011, Pages 103-110

  Inoue, T ^a   Taguchi, I ^a   Abe, S ^a   Toyoda, S ^a   Sakuma, M ^b   Node, K ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

cholestanol; cholesterol; cholesterol absorption; low density lipoprotein cholesterol; telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTESTINE ABSORPTION; LIPID METABOLISM; MALE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; CHOLESTANOL; CHOLESTEROL; CHOLESTEROL, LDL; FATTY ACIDS, MONOUNSATURATED; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDOLES; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PPAR GAMMA;

EID: 78650940867     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01161.x     Document Type: Article

References (25)

1. Benson SC, Pershadsingh HA, Ho CI, et al., (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 43, 993-1002.
2. Schupp M, Janke J, Clasen R, Unger T, Kintscher U, (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-gamma activity. Circulation, 109, 2054-2057.
3. Mori Y, Itoh Y, Tajima N, (2007) Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. American Journal of Hypertension, 20, 431-436.
4. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H, (2006) Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension, 48, 1-7.
5. Inoue T, Node K, (2008) Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opinion on Pharmacotherapy, 9, 1397-1406.
6. Inoue T, Morooka T, Moroe K, Ikeda H, Node K, (2007) Effect of telmisartan on cholesterol levels in patients with hypertension-Saga Telmisartan Aggressive Research (STAR). Hormone and Metabolic Research, 39, 1-5.
7. Miettinen TA, Koivisto P, (1983) Non-cholesterol sterols and bile acid production in hypercholesterolaemic patients with ileal bypass. In:, Paumgartner G, Stiehl A, Gerok W, eds. Bile acids and cholesterol in health and disease. Lancaster PA: MTP Press, 183-187.
8. Miettinen TA, Tilvis RS, Kesäniemi YA, (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. American Journal of Epidemiology, 131, 20-31.
9. Miettinen TA, Tilvis RS, Kesäniemi YA, (1998) Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle aged men. Metabolism, 38, 136-140.
10. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR, (1996) Cross-talk between the insulin and angiotensin signaling systems. Proceedings of the National Academy of Sciences of the United States of America, 93, 12490-12495. (Pubitemid 26367171)
11. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP, (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. The Journal of Clinical Investigation, 100, 2158-2169.
12. Folli F, Saad MJA, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR, (1999) Crosstalk between insulin and angiotensin II signaling system. Experimental and Clinical Endocrinology and Diabetes, 107, 133-139.
13. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R, (2004) Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism, and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Hypertension Research, 27, 457-464.
14. Gylling H, Miettinen TA, (2002) Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis, 160, 477-481.
15. Miettinen TA, Gylling H, Strandberg T, Sarna S, (1998) Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. British Medical Journal, 316, 1127-1130.
16. Hoenig MR, Rolfe BE, Campbell JH, (2006) Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis, 184, 247-254.
17. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H, (2003) Finnish Treat-to-Target Study Investigators. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. Journal of Laboratory and Clinical Medicine, 141, 131-137.
18. Miettinen TA, Strandberg TE, Gylling H, (2000) Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1340-1346.
19. Repa JJ, Turley SD, Lobaccaro JA, et al., (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science, 289, 24-29.
20. Berge KE, Tian H, Graf GA, et al., (2000) Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjuscent ABC transporters. Science, 290, 1771-1775.
21. Hoekstra M, Kruijt JK, van Eck M, van Berkel TJC, (2003) Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. The Journal of Biological Chemistry, 278, 25448-25453.
22. Schupp M, Clemenz M, Gineste R, et al., (2005) Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity. Diabetes, 54, 3442-3452.
23. Francis GA, Annicotte J, Auwerx J, (2002) Liver X receptors: Xcreting Xol to combat atherosclerosis. Trends in Molecular Medicine, 8, 455-458.
24. Diamant M, Heine RJ, (2003) TZDs in type 2 diabetes mellitus: current clinical evidence. Drugs, 63, 1373-1405.
25. Takata Y, Chu V, Collins AR, et al., (2005) Transcriptional repression of ATP-binding casette transporter A1 gene in macrophages. Circulation Research, 97, e88-e96.